Table 1 Baseline characteristics of patients with organophosphate poisoning, stratified according to diabetes mellitus status (N = 118)

Age, years (mean ± SD)

53.45 ± 16.20

52.32 ± 16.04

67.11 ± 11.84

0.008**

Male, n (%)

77 (65.3)

73 (67.0)

4 (44.4)

0.173

Organophosphate type, n (%):

0.082

Chlorpyrifos

48 (40.7)

44 (40.4)

4 (44.4)

Profenofos

16 (13.6)

16 (14.7)

0 (0.0)

Methamidophos

14 (11.9)

14 (12.8)

0 (0.0)

Mevinphos

10 (8.5)

9 (8.3)

1 (11.1)

Dimethoate

9 (7.6)

8 (7.3)

1 (11.1)

Malathion

6 (5.1)

5 (4.6)

1 (11.1)

Parathion

4 (3.4)

4 (3.7)

0 (0.0)

Acephate

3 (2.5)

2 (1.8)

1 (11.1)

Trichlorfon

3 (2.5)

3 (2.8)

0 (0.0)

Terbufos

2 (1.7)

2 (1.8)

0 (0.0)

Dichlorvos

1 (0.8)

1 (0.9)

0 (0.0)

Fenamiphos

1 (0.8)

1 (0.9)

0 (0.0)

Phorate

1 (0.8)

0 (0.0)

1 (11.1)

Organophosphate toxicity, n (%):

0.206

Ia, extremely hazardous

17 (14.4)

15 (13.8)

2 (22.2)

Ib, highly hazardous

16 (13.6)

16 (14.7)

0 (0.0)

II, moderately hazardous

76 (64.4)

71 (65.1)

5 (55.6)

III, slightly hazardous

9 (7.6)

7 (6.4)

2 (22.2)

U, unlikely to present acute hazard

0 (0)

0 (0)

0 (0)

Hypertension, n (%)

21 (17.8)

18 (16.5)

3 (33.3)

0.199

Old stroke, n (%)

10 (8.5)

8 (7.3)

2 (22.2)

0.123

Coronary artery disease, n (%)

3 (2.5)

3 (2.8)

0 (0.0)

0.614

Structural heart disease, n (%)

11 (9.3)

10 (9.2)

1 (11.1)

0.848

Chronic obstructive pulmonary disease, n (%)

9 (7.6)

8 (7.3)

1 (11.1)

0.682

Malignancy, n (%)

3 (2.5)

3 (2.8)

0 (0.0)

0.614

Mental disorder, n (%)

51 (43.2)

46 (42.2)

5 (55.6)

0.437

Smoking habit, n (%)

52 (44.1)

50 (45.9)

2 (22.2)

0.170

Alcohol consumption, n (%)

49 (41.5)

47 (43.1)

2 (22.2)

0.221

Use of medications that might be associated with QTc 7prolongation, n (%):

Antiarrhythmic agents

20 (16.9)

17 (15.6)

3 (33.3)

0.173

Antipsychotics and antidepressants

30 (25.4)

27 (24.8)

3 (33.3)

0.571

Antimicrobials

10 (8.5)

9 (8.3)

1 (11.1)

0.768